Comparison Between Rituximab Treatment for New-Onset Generalized Myasthenia Gravis and Refractory Generalized Myasthenia Gravis

IMPORTANCE: Use of biologic agents in generalized myasthenia gravis is generally limited to therapy-refractory cases; benefit in new-onset disease is unknown. OBJECTIVE: To assess rituximab in refractory and new-onset generalized myasthenia gravis and rituximab vs conventional immunotherapy in new-o...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:JAMA Neurol
Main Authors: Brauner, Susanna, Eriksson-Dufva, Ann, Hietala, Max Albert, Frisell, Thomas, Press, Rayomand, Piehl, Fredrik
Formato: Artigo
Idioma:Inglês
Publicado: American Medical Association 2020
Assuntos:
Original Investigation
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC7199182/
https://ncbi.nlm.nih.gov/pubmed/32364568
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaneurol.2020.0851
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares